This guideline is for the use of a variable rate intravenous insulin infusion (VRIII) in adult inpatients with medical conditions and diabetes/hyperglycaemia, who require intravenous administration of insulin to keep their blood glucose within the recommended target range during an acute illness or a period of starvation.
This guideline is not suitable for use in certain situations. We make the following recommendations for those circumstances.
Scope of the guideline
This document is designed to guide non specialist teams in the appropriate and safe use of a VRIII.
Seek help from your local diabetes team at the earliest opportunity.
Diabetic Ketoacidosis (DKA)
The [27] [28] It is recognised that the use of a variable rate intravenous insulin infusion (VRIII) is a tool commonly used to achieve normoglycaemia in hospital inpatients.
Most acute trusts have guidelines for its use, but there is a wide variation across the country in, for example, the indications for its use, in rates of infusion, or duration of use. This heterogeneity increases the risk of errors which can potentially lead to significant morbidity and mortality. It also makes it inherently difficult to study its efficacy, optimisation and safety profile. In addition, despite guidelines, both local and national audits have shown that VRIII is often used when not indicated, its duration is unnecessarily prolonged and the step down to other glucose lowering medication is often not practiced safely.
It is also acknowledged that achieving optimal glycaemia in this group of often complex patients, is not easy to achieve and individual targets are often needed.
In response to these issues, the Joint British Diabetes Societies (JBDS) for Inpatient Care has produced this guideline. It has been designed to be a practical guide to be used by any healthcare professional who manages medical in-patients with hyperglycaemia. Its main aim is to allow the VRIII to be used safely, effectively and efficiently for this specific group of inpatients. It is divided into several sections, including the evidence base for its recommendations, the practicalities of when to use a VRIII, how it is to be set up, when it should be discontinued and how a safe transition to other medication can be achieved. Safety of the use of the VRIII is emphasised throughout.
The appendices have been designed to be used as standalone summary documents, i.e. 'how to guides' which can be easily adapted and used on the wards.
It is hoped that its adoption nationally will help harmonise the the use of the VRIII and therefore enable multicentre studies to be carried out, and thus allow continual refinement in its use.
Foreword
Variable Rate Intravenous Insulin Infusion (VRIII), formerly known as sliding scale insulin, has been used for decades to achieve normoglycaemia in hospitals. It is a very useful tool when used in the right context and has been shown to improve outcomes. However, when used incorrectly, it can result in morbidity from hypoglycaemia, excess length of stay, rebound hyperglycaemia and even DKA 1 .
Guidelines already exist for patients with DKA, HHS, stroke, myocardial infarction and those in the perioperative period. The writing group have also worked in conjunction with the authors of the JBDS perioperative guidelines and have agreed a scale that will be concordant across both guidelines. This will be reflected in the revised surgical guideline, currently in development.
This guideline is designed for acutely unwell patients, including those with a pre-existing diagnosis of diabetes and those who present with hyperglycaemia for the first time.
The guideline is intended for use by any healthcare professional who manages patients with diabetes on hospital wards. It aims to be a practical guide for when and how to use an intravenous insulin infusion and how to transition patients to other glucose lowering medication after stabilisation.
Most studies of the use of intravenous insulin infusions in hospital have been in the critical care setting or in patients who have undergone surgery.
To date there is only one randomised trial focused on the management of medical inpatients 2 . This compared the use of different types of subcutaneous insulin regimens in the management of acutely unwell patients with Type 2 diabetes and did not assess the effectiveness of an intravenous insulin infusion.
The recommendations in this guideline are therefore based on a combination of:
• extrapolated evidence from other relevant patient groups
• guidelines from other JBDS groups where relevant
• NHS Diabetes e-learning module 'Safe use of Intravenous insulin infusion'
• consensus of experts who contributed to the development of this guideline Until advances in technology produce a system that can automatically adjust the insulin infusion rate in response to changes in the blood glucose, the safe and effective use of a VRIII will depend on close monitoring and decision making by health care professionals. The emphasis throughout this guideline is on the safe use of a VRIII when clinically indicated, aiming for target blood glucose levels that are appropriate for this group of patients. It should be used for as short a duration as possible, with plans for a safe and effective step-down to other agents as soon as the clinical situation allows.
Referral to local diabetes teams as soon as possible after admission is ideal since individual patients' needs must be assessed and appropriate action taken to ensure the VRIII is used safely. However, this may not be possible in some trusts depending on availability so local policies should be followed.
Introduction

Background
Approximately 15% of hospital inpatients have diabetes 1 of whom 70% are admitted as medical emergencies, the majority with diabetes as a secondary diagnosis. There is evidence from both medical and surgical settings to indicate that if the blood glucose is not controlled the outcomes, measured by mortality, morbidity or length of stay, are worse 3 .
While the evidence that lowering the blood glucose to a specified target range improves outcomes is more limited, it has been shown to be beneficial in some settings 4 . This is discussed in more detail in Chapter 2.
In the acute setting the options for controlling blood glucose are limited. On some occasions it may be possible to achieve glycaemic control using subcutaneous insulin but this requires a degree of expertise. If the diabetes team is not available to advise, the method of choice in an unwell or fasting patient is a VRIII -previously known as a sliding scale. This guideline specifies the clinical circumstances in which a VRIII should be used and how it should be initiated, managed and discontinued safely.
Definition of a variable rate intravenous insulin infusion
The infusion of intravenous insulin at a variable rate according to regular capillary blood glucose measurements with the aim of controlling serum glucose levels within a specified range. The VRIII is usually accompanied by an infusion of fluid containing glucose to prevent insulin-induced hypoglycaemia.
Classification of hyperglycaemia in acutely unwell patients
Known Diabetes
Diabetes diagnosed and treated before admission.
Newly diagnosed diabetes
Fasting glucose greater than 7.0 mmol/L or random glucose greater than 11.1 mmol/L during hospital stay and confirmed after discharge.
Hospital-related hyperglycaemia (also known as stress hyperglycaemia) 5 .
Fasting glucose greater than 7.0 mmol/L or random glucose greater than 11.1 mmol/L during hospital stay but glucose tolerance reverts back to the normal range after discharge.
Use of a VRIII in UK hospitals
The National Diabetes Inpatient Audit
The annual National Diabetes Inpatient Audit 1 , a snapshot audit of diabetes inpatient care in England and Wales, has yielded some important findings relating to the real world use of VRIII.
Inappropriate use:
6.5% of patients were thought to have been treated with a VRIII unnecessarily.
Inappropriate duration of use: In 2012, 10.6% of inpatients with diabetes received an insulin infusion during the previous 7 days, of whom 7.8% were treated with an insulin infusion for 7 days or longer. 7.7% of insulin infusions were deemed unnecessarily long by the diabetes team.
Inadequate monitoring:
1.7% of patients on an insulin infusion had between 1 and 3 glucose measurements in the previous 24 hours (equivalent to less than one every eight hours), with 0.8% having no glucose monitoring in the previous 24 hours.
Chapter 1: Background and definitions
Dynamic Sliding Scale Intravenous Insulin Regimes
Some centres in the UK and the US use both the current blood glucose level as well as the previous blood glucose level to determine the rate of insulin to be infused -a 'dynamic sliding scale' 6 . This way of delivering a VRIII is quite different to that used by the majority of UK centres. To date there have been no studies comparing these two methods of insulin delivery and until a comparative study is available, we recommend the traditional UK method as described in this document because of the wider clinical experience and greater simplicity of use.
Combined Glucose, Potassium, Insulin Infusions (GKI, GIK regimes)
Some centres in the UK use infusions where all three solutes are in one infusion bag for indications similar to the use of a VRIII as well as in surgical patients. This is outside the scope of this document which deals solely with the use of a VRIII regime in medical inpatients.
The physiological release of catabolic hormones during illness may lead to loss of blood glucose control in people with diabetes and can cause stressrelated hyperglycaemia in those not previously known to have diabetes 5 . There is good evidence from a variety of clinical areas to demonstrate that hyperglycaemia during inter-current illness is related to adverse outcomes, but studies designed to demonstrate the benefits of restoring good glycaemic control and to identify treatment targets have produced conflicting results.
The discussion below concentrates in the main on the available evidence for medical inpatients, the target population for this guideline. The evidence for surgical inpatients is discussed comprehensively in the JBDS Perioperative Guideline which can be accessed at www.diabetologists-abcd.org.uk or www.diabetes.org.uk. This guideline is currently under review.
Evidence for adverse effect of hyperglycaemia on outcomes during illness
Hyperglycaemia in hospitalised patients, whether the diabetes is previously known or undiagnosed and irrespective of its cause, is unequivocally associated with adverse outcomes, e.g. critically ill patients 7-14 , patients suffering an acute myocardial event [15] [16] [17] [18] , after surgical procedures [19] [20] [21] [22] , and in sepsis 23 .
Hyperglycaemia in hospital is associated with a significantly increased risk of mortality 3 . In a study by Umpierrez, this risk was shown to be even higher in patients not previously known to have diabetes (16% compared to 3% known diabetes and 1.7% normoglycaemia) 24 . Hyperglycaemia was also associated with increased length of stay, increased risk of requiring admission to intensive care and greater likelihood of discharge to residential or nursing home. It is not clear if these poor outcomes are due to the elevated glucose levels per se, or whether the elevated glucose levels merely serve as an indication of the severity of the underlying disease.
Evidence for specific blood glucose targets
Intervention directed at reducing blood glucose (BG) concentrations has resulted in improved outcomes in some studies, but not all 7-12, [14] [15] [16] [17] [18] [19] [20] [21] [23] [24] [25] [26] . Several recent clinical trials in critically ill patients have reported no reduction in mortality from intensive insulin treatment (IIT) (target near normoglycaemia) compared with conventional management (target BG <10.0 mmol/L). Some of these studies report harm associated with intensive insulin regimes, with increased rates of severe hypoglycaemia and, in one study, increased mortality 10-14, 23 .
Glycaemic Control in Intensive Care units (ICU)
Most of the studies investigating the optimal blood glucose targets for patients treated with intravenous insulin infusions have been in the critical care setting. Several studies have compared intensive insulin therapy (IIT), in which the aim was to achieve a blood glucose target of 4.0-6.0 mmol/L, with conventional insulin treatment (CIT) usually aiming for 6.0-10.0 mmol/L ( Table 1 ).
In the Leuven I study 7 , IIT was associated with a reduction in ICU mortality from 8% to 4.6% and in-hospital mortality from 10.9% to 7.2% amongst surgical ICU patients (mainly cardiac surgery), but a second study from the second unit (Leuven II) 12 showed no mortality benefit in medical ICU patients. However, when patients who required fewer than 3 days in ICU were excluded, IIT conveyed a significant benefit over CIT (43% vs. 52.5%; p=0.009).
Two further studies, NICE SUGAR 11 and COIITSS 27 found an increased risk of severe hypoglycaemia in Chapter 2: Evidence base for recommendations patients randomised to receive IIT and in NICE SUGAR this was also associated with an increased 90 day mortality.
It appears though, that it is not simply a matter of relaxing thresholds and treatment targets. In a retrospective study, Lanspa et al 28 Thus the picture seems to be more complicated and different patient groups appear to need different targets. Indeed, Van den Berghe commented that "the controversy on how to optimally treat hyperglycaemia in the ICU is continuing" 29 . 
Glycaemic Control in Hospitalised Medical Patients in Non-ICU Settings
Several observational studies point to a strong association between hyperglycaemia and poor clinical outcomes, including prolonged hospital stay, infection, disability after discharge from the hospital, and death 24, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Several studies have found glucose variability to be an independent predictor of mortality in critically ill patients [43] [44] [45] . Whether intervention to control glycaemic variability, per se, improves outcomes is not known.
There remains conflicting evidence about the choice of insulin therapy to obtain glycaemic control. One study, Rabbit 2, 46 found a variable regime based on basal-bolus subcutaneous insulin, controlled acute hyperglycaemia in insulin-naïve patients with type 2 diabetes more effectively than a subcutaneous 'sliding scale' regime where 4 injections were given per day with no basal insulin. However, the findings cannot necessarily be extrapolated to other groups of patients and comparison with VRIII was not made. In addition, these patients were reviewed daily by an endocrinologist and this level of input is not readily available in most UK trusts at present.
Glycaemic Control in Acute Myocardial infarction (AMI)
The DIGAMI 1 study 15 was the first randomised control trial to show the benefit of lowering blood glucose in patients with AMI. In this study the starting glucose was 15.7 vs 15.4 mmol/L (control vs intervention groups). Patients in the intervention group were treated with an insulin infusion for the first 24 hours, followed by 3 months of intensive (basal bolus) insulin therapy. During the first 24 hours blood glucose decreased significantly in both groups, with a greater decrease in the infusion group (5.8 ± 4.9 vs. 4.0 ± 3.9 mmol/L, p < 0.0001). This resulted in a reduction in mortality at 1 year (8.6% vs. 26 .1% (p < 0.0273) and 3.4 years (33% vs. 44% p <0.011) respectively. However, the relative contributions of the initial infusion compared with the following three months of intensive insulin treatment in improving outcomes were not established.
Although this initial glycaemic study showed potential benefit of intravenous insulin, further studies were not positive, possibly due to problems with design [47] [48] [49] [50] [51] .
Analysis of the UK MINAP (Myocardial Ischaemia
National Audit Project) data showed that admission glucose was strongly associated with mortality in all presentations of acute myocardial infarction irrespective of established diabetes diagnosis 52 .
Based on current evidence, NICE recommends the use of a dose adjusted intravenous insulin to prevent uncontrolled hyperglycaemia (BG >11.0 mmol/L) in patients with acute coronary syndrome (ACS). Regular BG monitoring is advised, aiming for moderate glycaemic control target BG <11 mmol/L with avoidance of intensive glycaemic control and hypoglycaemia 53 .
Hyperglycaemia in Acute Stroke
There is ample evidence to demonstrate that hyperglycaemia on admission is associated with worsened clinical outcome in patients with an acute stroke 35, 54, 55 . Good glycaemic control may also be indicated in patients without diabetes, in whom stress hyperglycaemia has been associated with a 3-fold risk of fatal 30-day outcome and 1.4fold risk of poor functional outcome, when compared with normoglycaemic patients 35 .
Guidelines from national and international societies
Several national and international societies have produced guidelines advising on glycaemic targets with regards to different patient populations -the majority are aimed at patients in the ITU setting. These are summarised in Table 2 . (1) Hyperglycaemia in hospital is associated with worse outcomes, whether people are known to have diabetes or not.
(2) There is limited evidence for a threshold for starting intravenous insulin therapy in a medically unwell patient but the consensus view recommends initiation of intravenous insulin if the CBG is greater than 10.0 mmol/L.
(3) Target blood glucose levels have not been established in trials but there is consensus for a range between 6-10 mmol/L. This range should avoid the risks associated with both hyperglycaemia and hypoglycaemia.
Indications for VRIII in medical patients
The majority of acutely unwell medical patients can be managed without a VRIII. Avoid intravenous insulin if the patient is eating and drinking normally. Consult the diabetes team who may be able to adjust the patient's own insulin regime. Follow local policy or see Appendix 4 for management of hyperglycaemia if the criteria for use of a VRIII (Box 1) are not met. In an attempt to increase safety, some hospital trusts in the UK use prefilled / pre-prepared insulin syringes for use in a VRIII. These are prepared in trust pharmacies with rigorous quality controls or have been procured from commercial sources. There is no current published data to evidence that this leads to increased safety when compared to syringes prepared at the time of need.
Suggested insulin infusion rates
Patients have different degrees of insulin sensitivity and insulin resistance related to weight, concurrent illness, medication (particularly steroids) etc. and may require a change in the rate of insulin infusion, depending on the blood glucose response to the initial rate.
Three insulin rates are recommended in Table 3 • Reduced rate for patients thought to be insulin sensitive The half life of intravenous insulin is very short (7-8 minutes) and restarting the VRIII promptly minimises the risk of ketosis.
These rates are starting points only and the prescribing doctor must be prepared to adapt the insulin infusion rate for the individual patient depending on the blood glucose response. Advice should be sought from the diabetes team if the target range is not achieved and maintained. The blood glucose response to the VRIII should be reviewed frequently and a doctor contacted to change the prescription if the target range is not achieved within the specified time frame.
If capillary blood glucose readings remain out of target:
1. Ensure that the cannula is patent 2. Ensure the infusion equipment is working appropriately 3. Ensure that the substrate infusion is running at the correct rate If all the above criteria are correct, the insulin infusion rate should be altered as follows:
CBG above target (greater than12 mmol/L and not falling* on two or more consecutive occasions):
• Increase the insulin infusion rate to the next scale
• If the patient is already on the increased rate, prescribe a customised insulin infusion rate and seek advice from the diabetes team as soon as possible *Take into account the initial CBG; for example, if this is 27 mmol/L it will take more than 3 hours for it to fall to target ranges and provided there is a steady fall in the CBG the insulin rate should not be adjusted.
CBG consistently 'too tight' (CBG levels between 4 and 6 mmol/L on two or more consecutive occasions).
(Although these levels are within target this may be too low for many patients -particularly those with CVA or ACS.)
• Consider reducing to a lower insulin infusion rate (Table 4 ).
2.
Patients with type 2 diabetes may also be prone to ketone production if unwell. We recommend ketone testing in this group of patients when presenting with acute illness. We do not recommend the routine use of capillary blood ketone testing in hyperglycaemic patients with Type 2 diabetes who are not acutely unwell. 
Frequency of patient review and the continuing need for the VRIII
This cohort of patients is likely to be elderly and have multiple co-morbidities which may be adversely affected by prolonged treatment with a VRIII.
Patients treated with a VRIII should be reviewed at least daily to:
• ensure progress and recovery in their presenting illness • monitor fluid balance • reassess the need for the VRIII
Choice of Concurrent Fluids
Aim of the fluid infusion:
• Avoid hypoglycaemia by providing substrate at a steady rate for the insulin infusion No concern of fluid overload 
Risk of fluid overload
Hyponatraemia or serum sodium falls by >3 mmol/L in 24 hr
Consider whether VRIII is essential or whether a subcutaneous insulin regime can be used If available use a mixed solution with higher sodium content such as 0.9% NaCl with 5% glucose and 0.3% KCl depending on potassium requirement OR Add 0.9% NaCl 42 ml/hr to run alongside glucose infusion, provided fluid overload is not a concern Renal or hepatic failure Use 'insulin sensitive' VRIII scale as these patients may have an increased risk of hypoglycaemia Seek specialist advice from nephrology/hepatology team regarding fluid management Second choice: 5% glucose with 40 mmol/L KCl at 125 ml/hr if serum K is 3.5-5.5 mmol/L
Duration of the VRIII
• The aim should be to convert back to standard (oral or subcutaneous) medication as soon as patients are able to eat and drink, provided the VRIII can be discontinued safely
• Avoid recommencing a VRIII if the patient becomes hyperglycaemic when the VRIII is withdrawn. Consult the diabetes team or see Appendix 4
• Consult the diabetes team if the patient had suboptimal diabetes control prior to the VRIII or has newly diagnosed diabetes
Management of other diabetes medications during a VRIII • Withhold usual diabetes treatment during VRIII
Most patients will have their usual diabetes medication completely withheld whilst they are on a VRIII including oral and injectable hypoglycaemic drugs as well as most forms of insulin. The exception is long acting analogue or isophane basal insulin, which should be continued (see below).
• Continue basal long-acting analogues* or isophane insulin** in patients usually taking multiple daily injections of insulin (MDI or basal-bolus insulin therapy).
• This may help control blood glucose during the VRIII and will avoid rebound hyperglycaemia once the patient's usual diabetes treatment is restarted 68 . This can help reduce the overall length of stay.
[*Detemir (Levemir ® ), *Glargine (Lantus ® ),* Degludec (Tresiba ® ), ** Insulatard ® ** Insuman Basal ® or** Humulin I ® ]
Transferring from a VRIII to subcutaneous insulin and/or oral treatment
Most patients will restart their usual diabetes treatment following a VRIII. Consult the diabetes team in the following circumstances for additional advice on ongoing management:
• diabetes control was sub-optimal prior to admission (recent pre-admission HbA1c >58 mmol/mol [7.5%])
• the patient can no longer manage their previous regime
• the patient cannot recall their previous insulin regime
• contraindications to previous therapy or new medical conditions have arisen • insulin commenced on this admission
It is important that patients receive education and support in self-management of diabetes, that they are confident to self-inject prior to discharge, and that follow-up support is available from appropriately trained professionals. 
Safe Use of Insulin
Errors in insulin prescribing are very common and insulin is one of the five highest-risk medications in the inpatient environment. The wide range of insulin preparations and administration devices increases the potential for error, and it is essential that staff are trained in the safe use of insulin. Dose errors can occur, such as where insulin is incorrectly prescribed, and management errors can cause harm through over -or under-dosing with insulin causing abnormal blood sugars.
The National Patient Safety Agency (NPSA) has made recommendations to promote the safe use of insulin and the Department of Health has added death or severe harm as a result of insulin maladministration to the list of 'Never Events' that are monitored by the NHS.
It is important that health care professionals follow this guidance and refer to local protocols to ensure safe prescribing is maintained.
We recommend that all healthcare professionals caring for patients with diabetes undertake all the relevant modules within the diabetes suite of e-learning available via the healthcare e-academy 69-72 .
Total Parenteral Nutrition (TPN)
Although detailed advice regarding total parenteral nutrition is beyond the scope of this guideline it is widely recognised that although TPN improves the nutritional status of critically ill patients 73 , it is associated with the short term complication of hyperglycaemia 74 .
Monitoring
• All patients receiving TPN should have their blood glucose levels checked at least twice in 24 hours but the frequency of monitoring should be increased if hyperglycaemia develops or if the patient has pre-existing diabetes. Achieving optimum glycaemic control can reduce morbidity and mortality in patients receiving TPN 73 .
• TPN provides essential glucose and electrolytes required in a 24 hour period. However, if the patient is fluid deplete, it may be necessary for additional fluids to be infused.
• If the blood glucose is elevated a VRIII will be required, in which case CBG should be monitored hourly. As for all patients receiving a VRIII, these patients will require daily venous blood glucose and urea and electrolytes. In addition other biochemical tests, e.g. micronutrients etc. may be needed. Consult your local nutrition and diabetes teams.
Delivery
• Intravenous Insulin must always be infused with a substrate; therefore if TPN is delivered via a multi lumen central line, the insulin must also be infused via its own dedicated central line lumen.
• If the TPN is to be delivered via a PICC line, it may be necessary to consider a double lumen PICC line. 
Cautions
Stepping down from a VRIII in patients on Total Parenteral Nutrition
Once glycaemic control is obtained patients should be stepped down to subcutaneous insulin as soon as possible. The regime chosen should reflect the fact the caloric intake will be a continuous infusion over 24 hours rather than, for instance, as 3 meals a day. The usual regimens of basal bolus or twice daily premixed insulin will not be suitable. In this special circumstance twice daily isophane insulin is recommended.
Once glycaemic control has been obtained on an intravenous infusion:
• Calculate the total daily dose of insulin used over 24 hours on TPN and prescribe as isophane insulin e.g. Humulin I or Insulatard
• Give 50% of the total daily dose at the start of the feed and 50% 12 hours later • Contact your local diabetes team for further advice
Patients on Continuous Subcutaneous Insulin Infusions (CSII) also known as Insulin Pumps
CSII is not recommended in situations where selfmanagement is unsafe as in the following:
• Acute illness preventing self-management • Diabetic Ketoacidosis (DKA) • ALWAYS commence VRIII before disconnecting CSII pump, since if the CSII pump is discontinued without an alternative provision of insulin, diabetic ketoacidosis is likely to develop within a short space of time because there is no reservoir of long-acting insulin.
• Once patient is well enough to self-manage recommence CSII and stop VRIII (as per stepdown guidance)
• Prior to resuming CSII, fill a new reservoir and re-site cannula
• Recommence CSII prior to a meal to allow a bolus to be given with the meal
• Discontinue the VRIII 30 minutes later
Check the BG 2 hours after the initial meal time bolus. If the BG is >14, pump manufacturer's hyperglycaemia guidelines should be followed. A correction should be given via the pump and glucose checked again 1 hour later. If glucose has risen or no improvement is seen, the cannula should be re-sited and the patient should be checked for ketones. This is to establish that the cannula is patent as the cannula may bend/kink on insertion, preventing insulin infusion.
• Patients who are no longer able to self-mange e.g. patients who have had a stroke, should be converted to an appropriate insulin regimen by the diabetes team.
Two registered nurses must check and prepare the VRIII and every time the rate of infusion is changed.
• *Although human Actrapid ® is the most commonly used insulin in VRIII, Insulin Aspart ® , Humulin S ® and Insulin Lispro ® can also be used as an alternative and have a licence for intravenous use. However these are more expensive alternatives.
In an attempt to increase safety, some hospital trusts in the UK use prefilled / pre-prepared insulin syringes for use in a VRIII. These are prepared in trust pharmacies with rigorous quality controls or have been procured from commercial sources. There is no current published data to evidence that this leads to increased safety when compared to syringes prepared at the time of need.
Appendix 1:
How to set up a VRIII General Principles Appendix 2: Safe discontinuation of VRIII Review diabetes treatments in all patients admitted with unstable blood sugars, and refer to diabetes in-patient team Do not discontinue the VRIII until 30 minutes after usual diabetes treatment has been restarted, and the patient is able to eat and drink Check the CBG one hour after discontinuing VRIII and at least four times for first 24 hours after VRIII has been discontinued, to ensure that there is no rebound hyperglycaemia i.e. pre-meal and pre-bed
Restarting Oral and Injectable Hypoglycemic Agents
Recommence oral and injectable hypoglycaemic agents once the patient is able to eat and drink.
Ensure that no contra-indications to the previous hypoglycaemic therapy have arisen. Review diabetes treatment in all patients admitted with unstable blood sugars, and refer to the in-patient diabetes team.
Diet alone Oral hypoglycaemic therapy
GLP-1 mimetics (injectable)
Discontinue VRIII when the patient is stable Restart usual diabetes treatment when a meal is due Do not stop VRIII until at least 30 minutes after treatment has been given and the patient has eaten Some patients may also be on basal insulin (see Table 6 for additional advice) 
Restarting insulin for patients previously on subcutaneous insulin
Convert to subcutaneous insulin when the patient is able to eat and drink and has managed at least one meal. Ideally the transfer should take place at a mealtime, usually breakfast or lunch. Ensure that background insulin (either long acting analogue or isophane) has been given before the VRIII is withdrawn 75 .
The VRIII should be continued until at least 30 minutes after the administration of a subcutaneous dose of insulin. This is to avoid rebound hyperglycaemia.
Most patients will restart their normal regime (see Table 6 for detailed advice). The pre-admission dose of insulin may need to be reduced if food intake is likely to be limited or the patient was admitted with low blood sugars.
Review diabetes treatment in all patients admitted with unstable blood glucose or HbA1c > 59 mmol/mol (7.5%), and refer to the diabetes in-patient team. 
Calculating subcutaneous insulin dose in insulin-naïve patients, or where insulin regime needs altering because of sub-optimal control
It is important that patients starting insulin receive education and support in selfmanagement of diabetes, that they are confident to self-inject prior to discharge, and that follow-up support is available from appropriately trained professionals
If the insulin dose is uncertain because the patient is new to insulin or has previously had poor control there are two possible ways of calculating the starting dose. There is no evidence on which to base a recommendation. The following guidelines are suggestions only, and detailed advice should be sought from local protocols and the diabetes team. 
Hyperglycaemia post VRIII
Capillary Blood Glucose (CBG) should be checked one hour after discontinuing VRIII and at least four times for the next 24 hours to ensure that there is no rebound hyperglycaemia i.e. pre-meal and pre-bed.
DO NOT recommence the VRIII if hyperglycaemia recurs unless the patient is clinically unwell.
General Guidance
1. Ensure that VRIII was discontinued appropriately with usual medication recommenced. Risk of rebound hyperglycaemia and possible ketoacidosis if intravenous access is lost unexpectedly or VRIII is stopped inappropriately.
2. If patient was previously on a basal insulin ensure this was continued with no gap in administration during VRIII.
If basal insulin was omitted in error this must be restarted before the VRIII is discontinued. If the basal insulin is not due for several hours, give half the usual dose of basal insulin, along with a meal and bolus insulin. This will provide essential background insulin until the usual dose can be recommenced.
3. Be aware that diabetes control may have been suboptimal control prior to admission. Check HbA1c and consider adjusting usual medication. Seek advice from the diabetes team for optimisation of their diabetes medication and ongoing management.
Specific Guidance
Blood glucose greater than 12.0 mmol/L with blood ketones less than 3.0 mmol/L or urine ketones no more than ++ Type 1 diabetes: give subcutaneous rapid acting analogue insulin *. Assume that 1 unit will drop blood glucose by 3 mmol/L BUT wherever possible take advice from the patient about the amount of insulin normally required to correct high blood glucose.
Recheck the blood glucose 1 hour later to ensure it is falling. Repeat the subcutaneous insulin dose after 2 hours if the blood glucose is still above 12.0 mmol/L. In this situation the insulin dose selected should take into account the response to the initial dose -consider increasing the dose if the response is inadequate.
Recheck the blood glucose after 1 hour. If it is not falling consider re-introducing VRIII.
Type 2 diabetes: give 0.1 units/kg of subcutaneous rapid acting analogue Insulin *, and recheck blood glucose 1 hour later to ensure it is falling.
Repeat the subcutaneous insulin after 2 hours if the blood glucose is still above 12.0 mmol/L. In this situation the insulin dose selected should take into account the response to the initial dose -consider doubling the dose if the response is inadequate.
Repeat the blood glucose after another hour. If it is not falling consider re-introducing VRIII.
* (rapid acting analogue insulin eg Novorapid ® , Humalog ® , Apidra ® ) 
Advice on long acting or 'basal' insulin
If the patient is on basal insulin, this must be continued alongside the VRIII.
If the basal insulin was omitted in error this must be restarted before the VRIII is discontinued. If the basal insulin is not due for several hours and you want to stop the VRIII, then give half the usual dose of basal insulin along with the meal and dose of rapid acting insulin. This will give essential background insulin until the usual dose can be recommenced. *If the CBGs have fallen below 4.0 mmol/L i.e. the patient has had a hypo, stop the VRIII and treat the hypoglycaemia. As soon as the CBG is >4 mmol/L restart the VRIII BUT at a reduced rate e.g. if the patient was on the standard rate when they had their hypo, restart the VRIII at the reduced rate. If the patient was already on the reduced rate scale, write up a new (further reduced) scale in the customised section. N.B. The half-life of intravenous insulin is very short (7-8 minutes) so the VRIII must be started as soon as possible after the CBG rises >4 mmol/L to minimise the risk of ketosis. 1 3.5-5.5 1 Litre 0.45% NaCl with 5% 125 glucose and 0.3% KCl (40 mmol/L) If infusion fluid 1 is not available use choice 2 as below 2 3.5-5.5 1 litre 5% glucose with 0.3%KCl 125 (40 mmol/L)
Note
If K is >5.5 mmol/L -no K is to be added to the infusion fluid If K is <3.5 mmol/L -senior review needed as extra potassium needs to be given Caution in those with eGFR <20 ml/min-may need less K You must take into account the patient's individual circumstances in terms of fluid requirements (below are suggestions and not a substitute for a thorough clinical assessment)
Dehydrated patient
Additional fluid required usually in the form of 0.9% NaCl. This can run alongside the glucose infusion
Frail elderly patient at risk of fluid overload
Reduce infusion fluid rate to 83 ml/hr i.e. 2 litres per 24 hours 3. Patients with severe heart or renal failure
May not be able to tolerate standard volumes of fluid. It may be necessary to use 10% glucose instead This should be prescribed as 500 ml of 10% glucose with 20 mmol/L KCl to run at 42 ml/hr 
